Skip to main content

Table 1 Details of drugs combined with bevacizumab

From: Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis

Combination drugs

Number of patients

Regimens

Group A

n = 44

 

 Gemcitabine and oxaliplatin

24

400 mg/m2 gemcitabine and 40 mg/m2 oxaliplatin on days 1, 8, and 15

 Pegylated liposomal doxorubicin

10

10 mg/m2 pegylated liposomal doxorubicin on days 1, 8, and 15

 Eribulin and oxaliplatin

5

1 mg/m2 eribulin and 40 mg/m2 oxaliplatin on days 1, 8, and 15

 Nivolumab

1

100 mg nivolumab on days 1 and 15, every 4 weeks

 Paclitaxel and carboplatin

1

175 mg/m2 paclitaxel and AUC 5 carboplatin on day 1

 Paclitaxel

1

80 mg/m2 paclitaxel on days 1, 8, and 15

 Trabectedin and oxaliplatin

1

0.25 mg/m2 trabectedin and 40 mg/m2 oxaliplatin on days 1, 8, and 15

 Trabectedin and pegylated liposomal doxorubicin

1

10 mg/m2 pegylated liposomal doxorubicin and 0.25 mg/m2 trabectedin on days 1, 8, and 15

Group B

n = 33

 

 Gemcitabine

32

1000 mg/m2 gemcitabine on days 1, 8, and 15

 Paclitaxel

1

80 mg/m2 paclitaxel on days 1, 8, and 15

  1. Group A was defined as patients treated with weekly low-dose administration of bevacizumab
  2. Group B was defined as patients treated with monthly high-dose administration of bevacizumab
  3. AUC Area under the curve